Brain

Hixny’s Snapshot Application Now Available to All Providers in New York

In a new SHIN-NY collaboration, Hixny has made it easy for providers across the stateto screen patients for HRSN and query the state's controlled substance database. ALBANY, N.Y., April 28, 2025 /PRNewswire/ -- Hixny, New York's cutting-edge health information…

8 months ago

PreveCeutical Closes Initial Tranche of Up-Sized Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),…

8 months ago

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA®…

8 months ago

Prime Biome (I’ve Tested It for 90 Days) Here’s My Honest Prime Biome Gummies Review And Shocking Results! (Good, Bad & Real)

Read this honest 90-day review of Prime Biome Gummies — Explore the real results, benefits, ingredients, side effects, and customer…

8 months ago

Symphony Robotics Welcomes Neurosurgery Leader Dr. Neil A. Martin as Chief Medical Officer to Revolutionize Glioblastoma Treatment with First-Ever MRI-Steerable Micro-Robotics

MIAMI, April 25, 2025 /PRNewswire/ -- Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, today announced the appointment of renowned…

8 months ago

TadHealth Announces $5.5 Million Dollar Series A Funding to Expand Mental Health Services in Schools

Series A Funding Led by Strategic Healthcare Executives NEWPORT BEACH, Calif.--(BUSINESS WIRE)--TadHealth, a leading provider of mental health technology solutions…

8 months ago

TadHealth Announces $5.5 Million Dollar Series A Funding to Expand Mental Health Services in Schools

Series A Funding Led by Strategic Healthcare Executives NEWPORT BEACH, Calif.--(BUSINESS WIRE)--TadHealth, a leading provider of mental health technology solutions…

8 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour  …

8 months ago